MEOBF (Mesoblast) Total Stockholders Equity : $461.26 Mil (As of Dec. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Mesoblast Total Stockholders Equity?

Mesoblast's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $461.26 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Mesoblast's Book Value per Share for the quarter that ended in Dec. 2024 was $0.40. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Mesoblast's Debt-to-Equity for the quarter that ended in Dec. 2024 was 0.27.

Mesoblast Total Stockholders Equity Historical Data

The historical data trend for Mesoblast's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mesoblast Total Stockholders Equity Chart

Mesoblast Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Total Stockholders Equity

Get a 7-Day Free Trial

549.33

581.40

497.04

501.84

480.36

Mesoblast Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Stockholders Equity	Get a 7-Day Free Trial															-	480.36	-	461.26	-

Mesoblast (OTCPK:MEOBF) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Mesoblast's Book Value per Share for the quarter that ended in Dec. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(461.262	-	0)	/	1156.509
	=	0.40

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Mesoblast's Debt-to-Equity for the quarter that ended in Dec. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(19.886	+	106.225)	/	461.262
	=	0.27

Mesoblast Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Mesoblast's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Mesoblast Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (OTCPK:MEOBF) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

MESO:USA LWB:Germany LWB1:Germany LWB:Germany MSB:Australia

Address

55 Collins Street, Level 38, Melbourne, VIC, AUS, 3000

Website

https://www.mesoblast.com

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.